Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) saw strong trading volume on Thursday . 443,856 shares changed hands during trading, an increase of 32% from the previous session’s volume of 336,586 shares.The stock last traded at $33.94 and had previously closed at $33.70.

Several equities research analysts recently issued reports on the company. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research note on Monday, May 2nd. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a research note on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research note on Monday, June 13th. Finally, Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $43.86.

The company has a 50-day moving average of $31.11 and a 200-day moving average of $28.14. The company’s market cap is $1.36 billion.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.02. The firm earned $2.71 million during the quarter, compared to analysts’ expectations of $1.25 million. Analysts expect that Seres Therapeutics Inc. will post ($1.81) EPS for the current year.

In related news, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the company’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total value of $27,600,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP John G. Aunins sold 18,640 shares of the company’s stock in a transaction on Monday, April 25th. The stock was sold at an average price of $31.94, for a total transaction of $595,361.60. Following the completion of the transaction, the executive vice president now directly owns 56,060 shares of the company’s stock, valued at approximately $1,790,556.40. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of MCRB. ProShare Advisors LLC purchased a new position in shares of Seres Therapeutics during the fourth quarter valued at $1,146,000. Morgan Stanley increased its position in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock valued at $1,185,000 after buying an additional 23,381 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock valued at $13,999,000 after buying an additional 7,259 shares in the last quarter.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.